Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Raises Price Target to $110

Benzinga Newsdesk www.benzinga.com Positive 73.0%

Neg 0% Neu 0% Pos 73%

Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and raises the price target from $105 to $110.